Persistent effects of chronic clozapine on the cellular and behavioral responses to LSD in mice

Psychopharmacology

Volumn 225, Issue 1, 2013, Pages 217-226

  Moreno, José L ^a   Holloway, Terrell ^a   Umali, Adrienne ^a   Rayannavar, Vinayak ^a   Sealfon, Stuart C ^a   González Maeso, Javier ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

GPCR; Hallucinogenic drugs; LSD; Mouse models; Schizophrenia

Indexed keywords

CLOZAPINE; EARLY GROWTH RESPONSE FACTOR 1; EARLY GROWTH RESPONSE FACTOR 2; HALOPERIDOL; KETANSERIN H 3; LYSERGIDE; PROTEIN C FOS; RADIOLIGAND; SEROTONIN 2A RECEPTOR; UNCLASSIFIED DRUG;

5 HT2A GENE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; EGR 1 GENE; EGR 2 GENE; GENE EXPRESSION; GENE INDUCTION; HEAD TWITCH; LIGAND BINDING; MALE; MOUSE; NONHUMAN; ONCOGENE C FOS; PRIORITY JOURNAL; SCHIZOPHRENIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; CLOZAPINE; DISEASE MODELS, ANIMAL; DOWN-REGULATION; HALLUCINOGENS; HALOPERIDOL; LYSERGIC ACID DIETHYLAMIDE; MALE; MICE; MICE, 129 STRAIN; PSYCHOTIC DISORDERS; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN 5-HT2 RECEPTOR AGONISTS; TIME FACTORS;

EID: 84872349473     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-012-2809-7     Document Type: Article

References (60)

1. Academies NRCotN (2011) Guide for the care and use of laboratory animals, Eightth edn. The National Academies Press, Washington, DC
2. Agid O, Kapur S, Arenovich T, Zipursky RB (2003) Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry 60:1228-1235
3. Baldessarini RJ, Centorrino F, Flood JG, Volpicelli SA, Huston-Lyons D, Cohen BM (1993) Tissue concentrations of clozapine and its metabolites in the rat. Neuropsychopharmacology 9:117-124
4. Beique JC, Imad M, Mladenovic L, Gingrich JA, Andrade R (2007) Mechanism of the 5-hydroxytryptamine 2A receptor-mediated facilitation of synaptic activity in prefrontal cortex. Proc Natl Acad Sci U S A 104:9870-9875
5. Black JE, Kodish IM, Grossman AW, Klintsova AY, Orlovskaya D, Vostrikov V, Uranova N, Greenough WT (2004) Pathology of layer V pyramidal neurons in the prefrontal cortex of patients with schizophrenia. Am J Psychiatry 161:742-744
6. Borison RL, Diamond BI, Sinha D, Gupta RP, Ajiboye PA (1988) Clozapine withdrawal rebound psychosis. Psychopharmacol Bull 24:260-263
7. Bradford AM, Savage KM, Jones DN, Kalinichev M (2010) Validation and pharmacological characterisation of MK-801-induced locomotor hyperactivity in BALB/C mice as an assay for detection of novel antipsychotics. Psychopharmacology (Berl) 212:155-170
8. Celada P, Puig MV, Diaz-Mataix L, Artigas F (2008) The hallucinogen DOI reduces low-frequency oscillations in rat prefrontal cortex: reversal by antipsychotic drugs. Biol Psychiatry 64:392-400
9. Cheng YF, Paalzow LK (1992) Linear pharmacokinetics of haloperidol in the rat. Biopharm Drug Dispos 13:69-76
10. Cheng YF, Lundberg T, Bondesson U, Lindstrom L, Gabrielsson J (1988) Clinical pharmacokinetics of clozapine in chronic schizophrenic patients. Eur J Clin Pharmacol 34:445-449
11. Choc MG, Lehr RG, Hsuan F, Honigfeld G, Smith HT, Borison R, Volavka J (1987) Multiple-dose pharmacokinetics of clozapine in patients. Pharm Res 4:402-405
12. Dobbs D (2010) Schizophrenia: The making of a troubled mind. Nature 468:154-156
13. Dong E, Nelson M, Grayson DR, Costa E, Guidotti A (2008) Clozapine and sulpiride but not haloperidol or olanzapine activate brain DNA demethylation. Proc Natl Acad Sci U S A 105:13614-13619
14. Freed WJ (1988) The therapeutic latency of neuroleptic drugs and nonspecific postjunctional supersensitivity. Schizophr Bull 14:269-277
15. Freedman R (2003) Schizophrenia. N Engl J Med 349:1738-1749
16. Garcia EE, Smith RL, Sanders-Bush E (2007) Role of G(q) protein in behavioral effects of the hallucinogenic drug 1-(2,5-dimethoxy-4-iodophenyl)-2- aminopropane. Neuropharmacology 52:1671-1677
17. Gewirtz JC, Marek GJ (2000) Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors. Neuropsychopharmacology 23:569-576
18. Geyer MA, Vollenweider FX (2008) Serotonin research: contributions to understanding psychoses. Trends Pharmacol Sci 29:445-453
19. Gilmore JH, Fredrik Jarskog L, Vadlamudi S, Lauder JM (2004) Prenatal infection and risk for schizophrenia: IL-1beta, IL-6, and TNFalpha inhibit cortical neuron dendrite development. Neuropsychopharmacology 29:1221-1229
20. Glantz LA, Lewis DA (2000) Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch Gen Psychiatry 57:65-73
21. Gonzalez-Maeso J, Sealfon SC (2009a) Agonist-trafficking and hallucinogens. Curr Med Chem 16:1017-1027
22. Gonzalez-Maeso J, Sealfon SC (2009b) Psychedelics and schizophrenia. Trends Neurosci 32:225-232
23. Gonzalez-Maeso J, Yuen T, Ebersole BJ, Wurmbach E, Lira A, Zhou M, Weisstaub N, Hen R, Gingrich JA, Sealfon SC (2003) Transcriptome fingerprints distinguish hallucinogenic and nonhallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex. J Neurosci 23:8836-8843
24. Gonzalez-Maeso J, Weisstaub NV, Zhou M, Chan P, Ivic L, Ang R, Lira A, Bradley-Moore M, Ge Y, Zhou Q, Sealfon SC, Gingrich JA (2007) Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron 53:439-452
25. Gonzalez-Maeso J, Ang RL, Yuen T, Chan P, Weisstaub NV, Lopez-Gimenez JF, Zhou M, Okawa Y, Callado LF, Milligan G, Gingrich JA, Filizola M, Meana JJ, Sealfon SC (2008) Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 452:93-97
26. Gouzoulis-Mayfrank E, Heekeren K, Neukirch A, Stoll M, Stock C, Daumann J, Obradovic M, Kovar KA (2005a) Inhibition of return in the human 5HT(2A) agonist and NMDA antagonist model of psychosis. Neuropsychopharmacology 31(2):431-441
27. Gouzoulis-Mayfrank E, Heekeren K, Neukirch A, Stoll M, Stock C, Obradovic M, Kovar KA (2005b) Psychological effects of (S)-ketamine and N, N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers. Pharmacopsychiatry 38:301-311
28. Gray JA, Roth BL (2007) Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophr Bull 33:1100-1119
29. Gray L, van den Buuse M, Scarr E, Dean B, Hannan AJ (2009) Clozapine reverses schizophrenia-related behaviours in the metabotropic glutamate receptor 5 knockout mouse: association with N-methyl-D-aspartic acid receptor up-regulation. Int J Neuropsychopharmacol 12:45-60
30. Hitchcock JM, Lister S, Fischer TR, Wettstein JG (1997) Disruption of latent inhibition in the rat by the 5-HT2 agonist DOI: effects of MDL 100,907, clozapine, risperidone and haloperidol. Behav Brain Res 88:43-49
31. Ichikawa J, Dai J, Meltzer HY (2001) DOI, a 5-HT2A/2C receptor agonist, attenuates clozapine-induced cortical dopamine release. Brain Res 907:151-155
32. Jann MW, Grimsley SR, Gray EC, Chang WH (1993) Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinet 24:161-176
33. Jones KA, Srivastava DP, Allen JA, Strachan RT, Roth BL, Penzes P (2009) Rapid modulation of spine morphology by the 5-HT2A serotonin receptor through kalirin-7 signaling. Proc Natl Acad Sci U S A 106:19575-19580
34. Kargieman L, Riga MS, Artigas F, Celada P (2011) Clozapine reverses phencyclidine-induced desynchronization of prefrontal cortex through a 5-HT(1A) Receptor-dependent mechanism. Neuropsychopharmacology 37:723-733
35. Kontkanen O, Lakso M, Wong G, Castren E (2002a) Chronic antipsychotic drug treatment induces long-lasting expression of fos and jun family genes and activator protein 1 complex in the rat prefrontal cortex. Neuropsychopharmacology 27:152-162
36. Kontkanen O, Toronen P, Lakso M, Wong G, Castren E (2002b) Antipsychotic drug treatment induces differential gene expression in the rat cortex. J Neurochem 83:1043-1053
37. Kristiansen LV, Huerta I, Beneyto M, Meador-Woodruff JH (2007) NMDA receptors and schizophrenia. Curr Opin Pharmacol 7:48-55
38. Kuoppamaki M, Seppala T, Syvalahti E, Hietala J (1993) Chronic clozapine treatment decreases 5-hydroxytryptamine1C receptor density in the rat choroid plexus: comparison with haloperidol. J Pharmacol Exp Ther 264:1262-1267
39. Lieberman JA, Bymaster FP, Meltzer HY, Deutch AY, Duncan GE, Marx CE, Aprille JR, Dwyer DS, Li XM, Mahadik SP, Duman RS, Porter JH, Modica-Napolitano JS, Newton SS, Csernansky JG (2008) Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacol Rev 60:358-403
40. Lin SK, Chang WH, Chung MC, Lam YW, Jann MW (1994) Disposition of clozapine and desmethylclozapine in schizophrenic patients. J Clin Pharmacol 34:318-324
41. MacDonald ML, Eaton ME, Dudman JT, Konradi C (2005) Antipsychotic drugs elevate mRNA levels of presynaptic proteins in the frontal cortex of the rat. Biol Psychiatry 57:1041-1051
42. Miyamoto S, Duncan GE, Marx CE, Lieberman JA (2005) Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 10:79-104
43. Morris BJ, Cochran SM, Pratt JA (2005) PCP: from pharmacology to modelling schizophrenia. Curr Opin Pharmacol 5:101-106
44. Nestler EJ, Hyman SE (2010) Animal models of neuropsychiatric disorders. Nat Neurosci 13:1161-1169
45. Nichols DE (2004) Hallucinogens. Pharmacol Ther 101:131-181
46. Ouagazzal A, Grottick AJ, Moreau J, Higgins GA (2001) Effect of LSD on prepulse inhibition and spontaneous behavior in the rat. A pharmacological analysis and comparison between two rat strains. Neuropsychopharmacology 25:565-575
47. Roth BL, Sheffler DJ, Kroeze WK (2004) Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 3:353-359
48. Sams-Dodd F (1998) A test of the predictive validity of animal models of schizophrenia based on phencyclidine and D-amphetamine. Neuropsychopharmacology 18:293-304
49. Sawa A, Snyder SH (2002) Schizophrenia: diverse approaches to a complex disease. Science 296:692-695
50. Schreiber R, Brocco M, Millan MJ (1994) Blockade of the discriminative stimulus effects of DOI by MDL 100,907 and the 'atypical' antipsychotics, clozapine and risperidone. Eur J Pharmacol 264:99-102
51. Singleton C, Marsden CA (1981) Circadian variation in the head twitch response produced by 5-methoxy-N1, N1-dimethyltryptamine and p-chloroamphetamine in the mouse. Psychopharmacology (Berl) 74:173-176
52. Smith RL, Barrett RJ, Sanders-Bush E (2003) Discriminative stimulus properties of 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane [(+/-)DOI] in C57BL/6J mice. Psychopharmacology (Berl) 166:61-68
53. Verma V, Rasmussen K, Dawe GS (2006) Effects of short-term and chronic olanzapine treatment on immediate early gene protein and tyrosine hydroxylase immunoreactivity in the rat locus coeruleus and medial prefrontal cortex. Neuroscience 143:573-585
54. Vollenweider FX, Leenders KL, Scharfetter C, Maguire P, Stadelmann O, Angst J (1997) Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology 16:357-372
55. Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Babler A, Vogel H, Hell D (1998) Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 9:3897-3902
56. Wang RY, Liang X (1998) M100907 and clozapine, but not haloperidol or raclopride, prevent phencyclidine-induced blockade of NMDA responses in pyramidal neurons of the rat medial prefrontal cortical slice. Neuropsychopharmacology 19:74-85
57. Willins DL, Meltzer HY (1997) Direct injection of 5-HT2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats. J Pharmacol Exp Ther 282:699-706
58. Winter JC, Kieres AK, Zimmerman MD, Reissig CJ, Eckler JR, Ullrich T, Rice KC, Rabin RA, Richards JB (2005) The stimulus properties of LSD in C57BL/6 mice. Pharmacol Biochem Behav 81:830-837
59. Yadav PN, Abbas AI, Farrell MS, Setola V, Sciaky N, Huang XP, Kroeze WK, Crawford LK, Piel DA, Keiser MJ, Irwin JJ, Shoichet BK, Deneris ES, Gingrich J, Beck SG, Roth BL (2011a) The presynaptic component of the serotonergic system is required for clozapine's efficacy. Neuropsychopharmacology 36:638-651
60. Yadav PN, Kroeze WK, Farrell MS, Roth BL (2011b) Antagonist functional selectivity: 5-HT2A serotonin receptor antagonists differentially regulate 5-HT2A receptor protein level in vivo. J Pharmacol Exp Ther 339:99-105